Risankizumab Risankizumab rzaa; BI 655066|cas:1612838-76-2|西域试剂

Risankizumab Risankizumab rzaa; BI 655066,97.70%

产品编号：Bellancom-P99248| CAS NO：1612838-76-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99248		￥6800.00	杭州北京（现货）
Bellancom-P99248		￥14800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Risankizumab Risankizumab rzaa; BI 655066

产品介绍

Risankizumab (BI 655066) 是一种人源化 IgG 单克隆抗体，靶向 IL-23 p19 亚基(K_d <10 pM)，并能抑制人 IL-23 在小鼠脾细胞中诱导的 IL-17 产生(IC₅₀ = 2 pM)。Risankizumab 可用于研究免疫性和炎症性疾病，如寻常型银屑病、银屑病关节炎、广泛性脓疱型银屑病和红皮病型银屑病。

生物活性

Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (K_d <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC₅₀ = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.

体外研究

Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with K_ds <10 pM.
Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC₅₀s of 2 pM and 17 pM, respectively.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days)
Dosage:	1 mg/kg
Administration:	i.p.; single dosage
Result:	Significantly inhibited IL23-induced ear swelling and cytokine production.

Animal Model:

Cynomolgus monkeys

Dosage:

1.0 mg/kg

Administration:

i.v. or s.c.

Result:

Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys.

	IV (1 mg/kg)	SC (1 mg/kg)
AUC_inf (μg·day/mL)	202 ± 33.5	142 ± 33.3
CL (mL/day/kg)	5.18 ± 0.8	/
Vd, ss (mL/kg)	88.3 ± 3.12	/
t_1/2 (h)	12.2 ± 2.28/	9.15 ± 1.87
C_max (μg/mL)	/	10.1 ± 3.14
T_max (day)	/	2.11 ± 1.84
F (%)	/	70.4 ± 16.5

体内研究

Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days)
Dosage:	1 mg/kg
Administration:	i.p.; single dosage
Result:	Significantly inhibited IL23-induced ear swelling and cytokine production.

Animal Model:

Cynomolgus monkeys

Dosage:

1.0 mg/kg

Administration:

i.v. or s.c.

Result:

Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys.

	IV (1 mg/kg)	SC (1 mg/kg)
AUC_inf (μg·day/mL)	202 ± 33.5	142 ± 33.3
CL (mL/day/kg)	5.18 ± 0.8	/
Vd, ss (mL/kg)	88.3 ± 3.12	/
t_1/2 (h)	12.2 ± 2.28/	9.15 ± 1.87
C_max (μg/mL)	/	10.1 ± 3.14
T_max (day)	/	2.11 ± 1.84
F (%)	/	70.4 ± 16.5